Share ownership Beam Therapeutics Inc.

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
27.93 ^USD	-5.42%		-13.58%	+0.76%

05-07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, vs. FactSet Est of $11.0M	MT

Share class: Beam Therapeutics Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	102,879,214	101,479,152 ( 98.64 %)	0	98.64 %

Major shareholders: Beam Therapeutics Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 12.12 %	12,452,199	12.12 %	378 M $
ARK Investment Management LLC 11.81 %	12,133,433	11.81 %	368 M $
Farallon Capital Management LLC 9.864 %	10,134,696	9.864 %	307 M $
BlackRock Advisors LLC 7.55 %	7,757,085	7.55 %	235 M $
STATE STREET CORPORATION 5.547 %	5,699,265	5.547 %	173 M $
Vanguard Capital Management LLC 4.986 %	5,122,475	4.986 %	155 M $
Vanguard Portfolio Management LLC 4.449 %	4,570,797	4.449 %	139 M $
ARCH Venture Partners LLC 4.419 %	4,540,132	4.419 %	138 M $
Vanguard Capital Management LLC 4.26 %	4,377,374	4.26 %	133 M $
Amova Asset Management Americas, Inc. 3.723 %	3,825,585	3.723 %	116 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	99.01%
State Street Corp.	5.55%
Other	3.56%
Individuals	1.79%
Alphabet, Inc.	0.31%
Schweizerische Nationalbank	0.18%
Manulife Financial Corp.	0.15%
SEI Investments Co.	0.05%
Banque Cantonale Vaudoise	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	94.29%
United Kingdom	7.63%
Australia	2.01%
Individuals	1.79%
France	1.08%
Ireland	1.05%
Switzerland	0.74%
Canada	0.68%
Bermuda	0.52%
China	0.19%
Germany	0.13%
Denmark	0.09%
Hong Kong	0.08%
Singapore	0.06%
Netherlands	0.06%
Cayman Islands	0.05%
Austria	0.04%
Poland	0.04%
Sweden	0.03%
Norway	0.02%
Japan	0.01%
Taiwan	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Employees

522

Sector

Biotechnology & Medical Research

More about the company